Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Mircea Dediu"'
Autor:
Catherine Copigneaux, Mircea Dediu, Kenji Hirotani, Kazuhiko Nakagawa, Shuquan Chen, Joachim von Pawel, Kimio Yonesaka
Publikováno v:
Lung Cancer. 105:1-6
Objectives Patritumab is a fully human anti-human epidermal growth factor receptor 3 (HER3) antibody that blocks activation by its ligand, heregulin (HRG). Preclinical studies have demonstrated the efficacy of patritumab in aberrantly high HRG-expres
Autor:
Nick, Thatcher, Fred R, Hirsch, Alexander V, Luft, Aleksandra, Szczesna, Tudor E, Ciuleanu, Mircea, Dediu, Rodryg, Ramlau, Rinat K, Galiulin, Beatrix, Bálint, György, Losonczy, Andrzej, Kazarnowicz, Keunchil, Park, Christian, Schumann, Martin, Reck, Henrik, Depenbrock, Shivani, Nanda, Anamarija, Kruljac-Letunic, Raffael, Kurek, Luis, Paz-Ares, Mark A, Socinski, Alexander, Spira
Publikováno v:
The Lancet Oncology. 16:763-774
Background: Necitumumab is a second-generation, recombinant, human immunoglobulin G1 EGFR antibody. In this study, we aimed to compare treatment with necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone in patients with p
Autor:
Patrick Peterson, Victoria Soldatenkova, Richard J. Gralla, Mircea Dediu, Nadia Chouaki, Martin Reck, Mark A. Socinski, Jacqueline Brown, György Losonczy, Christian Schumann, Alexander Luft, Rodryg Ramlau, Philip Bonomi, Nick Thatcher, Aleksandra Szczesna, Coleman K. Obasaju, Olivier Molinier
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 11(6)
Introduction Necitumumab, a second-generation, recombinant human immunoglobulin G1 epidermal growth factor receptor antibody in the phase 3 SQUIRE trial (NCT00981058), increased survival benefit for patients randomized to receive necitumumab plus gem
Autor:
Luis, Paz-Ares, Jörg, Mezger, Tudor E, Ciuleanu, Jürgen R, Fischer, Joachim, von Pawel, Mariano, Provencio, Andrzej, Kazarnowicz, György, Losonczy, Gilberto, de Castro, Aleksandra, Szczesna, Lucio, Crino, Martin, Reck, Rodryg, Ramlau, Ernst, Ulsperger, Christian, Schumann, Jose Elias A, Miziara, Álvaro E, Lessa, Mircea, Dediu, Beatrix, Bálint, Henrik, Depenbrock, Victoria, Soldatenkova, Raffael, Kurek, Fred R, Hirsch, Nick, Thatcher, Mark A, Socinski, Allan, Price
Necitumumab is a second-generation recombinant human immunoglobulin G1 EGFR monoclonal antibody that competitively inhibits ligand binding. We aimed to compare necitumumab plus pemetrexed and cisplatin with pemetrexed and cisplatin alone in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42fb9d849fc4f299b6ff6abf3bbc6bdd
http://hdl.handle.net/11391/1342869
http://hdl.handle.net/11391/1342869
Autor:
Martin Reck, Matthew Joseph Gribbin, Mircea Dediu, David R. Spigel, Cristina L. Cebotaru, D. Ross Camidge, Robin Humphreys, Jimmie H. Harvey, Joachim von Pawel, N. L. Fox
Publikováno v:
Clinical lung cancer. 15(3)
Background This phase II study examined the efficacy of mapatumumab in combination with paclitaxel and carboplatin in patients with non–small-cell lung cancer (NSCLC). Patients and Methods Patients with stage IIIB or stage IV advanced primary NSCLC